Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023.
COVID-19
Italy
Omicron XBB sublineages
bivalent mRNA vaccines
effectiveness
Journal
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
medline:
11
8
2023
pubmed:
10
8
2023
entrez:
10
8
2023
Statut:
ppublish
Résumé
During predominant circulation of SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages (April-June 2023), we found that a second or third booster of Comirnaty bivalent Original/Omicron BA.4-5 mRNA vaccine, versus a first booster received at least 120 days earlier, was effective in preventing severe COVID-19 for more than 6 months post-administration in persons 60 years and above. In view of autumn 2023 vaccination campaigns, use of bivalent Original/Omicron BA.4-5 mRNA vaccines might be warranted until monovalent COVID-19 vaccines targeting Omicron XBB.1 sublineages become available.
Identifiants
pubmed: 37561053
doi: 10.2807/1560-7917.ES.2023.28.32.2300397
pmc: PMC10416574
doi:
Substances chimiques
COVID-19 Vaccines
0
mRNA Vaccines
0
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Clin Infect Dis. 2023 Jun 06;:
pubmed: 37280047
Open Forum Infect Dis. 2023 Apr 19;10(6):ofad209
pubmed: 37274183
Lancet Infect Dis. 2023 Jul 18;:
pubmed: 37478878
MMWR Morb Mortal Wkly Rep. 2023 Feb 03;72(5):119-124
pubmed: 36730051
Lancet Infect Dis. 2023 Jul 18;:
pubmed: 37478877
N Engl J Med. 2023 May 11;388(19):1818-1820
pubmed: 37043647